Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy